CME: Advances in the Management of Moderate-to-Severe Atopic Dermatitis

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
Hello, there.


Submit your challenging patient case that could be featured in future educational programming.

Click HERE to engage with the experts!

Advances in the Management of Moderate-to-Severe Atopic Dermatitis

Advances in the Management of Moderate-to-Severe Atopic Dermatitis

This multidisciplinary faculty panel and a patient deliberate over challenging topics in moderate-to-severe atopic dermatitis.

Available credits: 0.50

Time to complete: 30 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    “I begged my doctor for something else – there had to be something else,” Pam.  

    For over 50 years, Pam suffered with uncontrolled moderate-to-severe atopic dermatitis (AD). She experienced the evolution of treatment strategies over the course of the several decades, trying everything from topicals to off-label targeted systemic agents. She was willing to try anything to make the unbearable itch go away. In this roundtable discussion, we brought Pam and her dermatologist to discuss AD with a multidisciplinary physician panel. Together they weigh in on experimental and newly approved therapies, management strategies, impact on quality-of-life, and shared decision-making techniques, all supplemented by Pam’s unfiltered, down-to-earth reality check of what life with AD and all these drugs really feels like. 

  • Faculty Credentials

    Peter A. Lio, MD - CHAIR
    Assistant Professor, Clinical Dermatology and Pediatrics
    Northwestern University
    Feinberg School of Medicine
    Ann & Robert H. Lurie Children’s Hospital
    Chicago, IL
    Mark Boguniewicz, MD
    Professor, Division of Allergy-Immunology 
    Department of Pediatrics
    National Jewish Health and University of Colorado School of Medicine
    Denver, CO
    Eric L. Simpson, MD, MCR
    Professor, Dermatology 
    Director, Clinical Research 
    Department of Dermatology 
    Oregon Health & Science University 
    Portland, OR 
  • Target Audience

    The target audience for this activity is US-based dermatologists, allergists, and immunologists, as well as NPs and PAs that diagnose and manage atopic dermatitis (AD). Primary care clinicians will also be included as a secondary audience.

  • Learning Objectives

    Upon successful completion of this activity, participants should be better able to:

    • Apply current principles of pathophysiology of atopic dermatitis (AD) and the concept of atopic march to therapeutic approaches to disease management 
    • Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, assessment of treatment response, and strategies to optimize short-term control and long-term management of the disease 
    • Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD 
    • Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes 
  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC (RMEI). AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians. AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Physician Assistants
    NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

  • Provider(s)/Educational Partner(s)


    This educational activity was independently developed by RMEI Medical Education, LLC, in collaboration with AKH Inc., Advancing Knowledge in Healthcare Inc.

  • Commercial Support

    This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

  • Disclosure of Conflicts of Interest

    It is the policy of AKH Inc. and RMEI to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    • Mark Boguniewicz, MD, has affiliations with Regeneron, Sanofi (Consultant); Regeneron (Contracted Research); Regeneron, Sanofi (Speakers Bureau)
    • Peter A. Lio, MD, has affiliations with Altus Labs, Dermavant Sciences, Derm Tap, Inc., DermVeda, IntraDerm Pharmaceuticals, gpower, Inc., Johnson & Johnson, Menlo Therapeutics, Micreos Human Health B.V., Modernizing Medicine, National Eczema Association, Realm Therapeutics, Regeneron, Sanofi U.S., Syncere Skin Systems, UCB, Verrica Pharmaceuticals, Inc. (Advisory Board); AbbVie, Dermira, Eli Lilly, Exeltis, Franklin BioScience, Galderma Laboratories, L.P, Johnson & Johnson, Kiniksa Pharmaceuticals, Ltd., L’Oréal USA Inc., Odeza, LLC, Theraplex, TopMD, Unilever, Valeant Pharmaceuticals International (Consulting); AbbVie, AOBiome, LLC, La Fondation pour la Dermatite Atopique, Regeneron, (Investigator); Galderma Laboratories, Johnson & Johnson, La Roche-Posay Laboratorie, Mission, Pierre Fabre Dermatologie, Pfizer, Regeneron, Valeant Pharmaceuticals North America, LLC (Speaker); Learn Health/Learn Skin, Medable, Modernizing Medicine (Stockholder)
    • Eric L. Simpson, MD, MCR, has affiliations with AbbVie Inc., Boehringer-Ingelheim, Dermo Cosmetique, Eli Lilly Co., Forte Bio, Incyte, Leo Pharmaceuticals Co., Menlo Therapeutics, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme (Consultant); Eli Lilly Co., Galderma, Incyte, Leo Pharmaceuticals Co., Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Kyowa Hakko Kirin, Target Pharma Solutions (Contracted Research)
    • Pamela P. Fantus, RN, MSN, Patient has disclosed no financial relationships.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

    RMEI Medical Education, LLC

    • Lobna Eldasher, PharmD, has no affiliations with commercial interests to disclose.
    • Sharon Powell, has no affiliations with commercial interests to disclose.

    AKH, Inc.

    • Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner, has no affiliations with commercial interests to disclose.
    • Patricia Brignoni, AKH Sr. Project Manager, has no affiliations with commercial interests to disclose.

    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

  • How to Receive Your Credit

    By reviewing the course content and successfully completing the post-test and evaluation, physicians and PAs are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity post-test and evaluation.

    Physicians and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at

  • Your Feedback is Important to Us


    *The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.

    Rules and Regulations 
    This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

  • Media

    Online, Web

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Programs 12/16/19